- Home
- IOBT vs INZY Comparison
IOBT vs INZY Comparison
Compare IOBT & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- INZY
- Stock Information
- Founded
- IOBT 2014
- INZY 2015
- Country
- IOBT Denmark
- INZY United States
- Employees
- IOBT 80
- INZY N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- INZY Health Care
- Exchange
- IOBT Nasdaq
- INZY Nasdaq
- Market Cap
- IOBT 56.5M
- INZY 64.9M
- IPO Year
- IOBT 2021
- INZY 2020
- Fundamental
- Price
- IOBT $0.86
- INZY $0.92
- Analyst Decision
- IOBT Strong Buy
- INZY Strong Buy
- Analyst Count
- IOBT 3
- INZY 9
- Target Price
- IOBT $9.33
- INZY $17.22
- AVG Volume (30 Days)
- IOBT 266.2K
- INZY 453.8K
- Earning Date
- IOBT 05-13-2025
- INZY 05-06-2025
- Dividend Yield
- IOBT N/A
- INZY N/A
- EPS Growth
- IOBT N/A
- INZY N/A
- EPS
- IOBT N/A
- INZY N/A
- Revenue
- IOBT N/A
- INZY N/A
- Revenue This Year
- IOBT N/A
- INZY N/A
- Revenue Next Year
- IOBT N/A
- INZY N/A
- P/E Ratio
- IOBT N/A
- INZY N/A
- Revenue Growth
- IOBT N/A
- INZY N/A
- 52 Week Low
- IOBT $0.66
- INZY $0.72
- 52 Week High
- IOBT $1.79
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- IOBT 41.66
- INZY 44.29
- Support Level
- IOBT $0.85
- INZY $0.83
- Resistance Level
- IOBT $0.94
- INZY $1.08
- Average True Range (ATR)
- IOBT 0.10
- INZY 0.11
- MACD
- IOBT -0.02
- INZY 0.02
- Stochastic Oscillator
- IOBT 8.13
- INZY 55.43
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.